Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Bitzer

Showing results (131-140 of 185) with videos related to

Pageof 19
Sort By:
Frontiers in Oncology|April 12, 2024
FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusionChristopher Hackenbruch, Jens Bauer, Jonas S Heitmann, et al.
JCO Precision Oncology|September 14, 2020
Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment OptionsMichael Bitzer, Leonie Ostermann, Marius Horger, et al.
BMC Bioinformatics|February 8, 2022
A data management infrastructure for the integration of imaging and omics data in life sciencesLuis Kuhn Cuellar, Andreas Friedrich, Gisela Gabernet, et al.
Cancers|December 23, 2020
Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular CarcinomaStephan Spahn, Daniel Roessler, Radu Pompilia, et al.
The Oncologist|October 1, 2025
Lenvatinib after progression on pemigatinib and futibatinib in FGFR2 fusion-positive biliary tract cancer with an acquired kinase point mutationFabian Kleinhenz, Nicole Pfarr, Lisa Steinhelfer, et al.
European Journal of Cancer (Oxford, England : 1990)|March 9, 2025
Precision oncology - Guideline of the Austrian, German and Swiss Societies for hematology and medical oncologyDamian T Rieke, Michael Bitzer, Annalen Bleckmann, et al.
Nature Communications|February 12, 2024
The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinomaStephan Spahn, Fabian Kleinhenz, Ekaterina Shevchenko, et al.
NPJ Precision Oncology|September 4, 2021
Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinomaMichael Bitzer, Stephan Spahn, Sepideh Babaei, et al.
Nature Communications|October 24, 2023
Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trialMaria Pouyiourou, Bianca N Kraft, Timothy Wohlfromm, et al.
BMC Cancer|March 1, 2020
High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08Martin Fehr, Hanne Hawle, Stefanie Hayoz, et al.
Pageof 19

Showing results (131-140 of 185) with videos related to

Sort By:
Pageof 19
Frontiers in Oncology|April 12, 2024
FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusionChristopher Hackenbruch, Jens Bauer, Jonas S Heitmann, et al.
JCO Precision Oncology|September 14, 2020
Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment OptionsMichael Bitzer, Leonie Ostermann, Marius Horger, et al.
BMC Bioinformatics|February 8, 2022
A data management infrastructure for the integration of imaging and omics data in life sciencesLuis Kuhn Cuellar, Andreas Friedrich, Gisela Gabernet, et al.
Cancers|December 23, 2020
Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular CarcinomaStephan Spahn, Daniel Roessler, Radu Pompilia, et al.
The Oncologist|October 1, 2025
Lenvatinib after progression on pemigatinib and futibatinib in FGFR2 fusion-positive biliary tract cancer with an acquired kinase point mutationFabian Kleinhenz, Nicole Pfarr, Lisa Steinhelfer, et al.
European Journal of Cancer (Oxford, England : 1990)|March 9, 2025
Precision oncology - Guideline of the Austrian, German and Swiss Societies for hematology and medical oncologyDamian T Rieke, Michael Bitzer, Annalen Bleckmann, et al.
Nature Communications|February 12, 2024
The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinomaStephan Spahn, Fabian Kleinhenz, Ekaterina Shevchenko, et al.
NPJ Precision Oncology|September 4, 2021
Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinomaMichael Bitzer, Stephan Spahn, Sepideh Babaei, et al.
Nature Communications|October 24, 2023
Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trialMaria Pouyiourou, Bianca N Kraft, Timothy Wohlfromm, et al.
BMC Cancer|March 1, 2020
High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08Martin Fehr, Hanne Hawle, Stefanie Hayoz, et al.
Pageof 19